
Tradename | Company | Number | Date | Products |
|---|---|---|---|---|
| EPCLUSA | Gilead Sciences | N-208341 RX | 2016-06-28 | 2 products, RLD, RS |
| EPCLUSA | Gilead Sciences | N-214187 RX | 2021-06-10 | 2 products, RLD, RS |
Tradename | Company | Number | Date | Products |
|---|---|---|---|---|
| HARVONI | Gilead Sciences | N-205834 RX | 2014-10-10 | 2 products, RLD, RS |
| HARVONI | Gilead Sciences | N-212477 RX | 2019-08-28 | 2 products, RLD, RS |
Tradename | Company | Number | Date | Products |
|---|---|---|---|---|
| SOVALDI | Gilead Sciences | N-204671 RX | 2013-12-06 | 2 products, RLD, RS |
| SOVALDI | Gilead Sciences | N-212480 RX | 2019-08-28 | 2 products, RLD, RS |
Tradename | Company | Number | Date | Products |
|---|---|---|---|---|
| VOSEVI | Gilead Sciences | N-209195 RX | 2017-07-18 | 1 products, RLD, RS |
Brand Name | Status | Last Update |
|---|---|---|
| OTC monograph not final | 2012-09-10 | |
| 2 in 1laxative stool softener and stiulant laxative | OTC monograph not final | 2022-01-03 |
| 3 concept eyes glossing waterful foundation soft beige | OTC monograph not final | 2013-10-03 |
| 3 concept eyes slim fit pact soft beige | OTC monograph not final | 2013-10-03 |
| 30 soft wipes | OTC monograph not final | 2022-12-08 |
| 60 soft wipes | OTC monograph not final | 2022-12-10 |
| acacia pollen american beech american elm american sycamore arizona ash arizona cypress ash mixture aspen pollen australian pine austrian pine bald... | Biologic Licensing Application, Bulk ingredient | 2009-11-19 |
| accentrate pnv | unapproved drug other | 2025-03-10 |
| acetaminophen 325 mg, dextromethorphan hydrobromide 10 mg, phenlyephrine hydrochloride 5 mg softgel (day-time) | C200263 | 2025-09-24 |
| alabaster beige expert finish makeup broad spectrum spf 25 bare expert finish makeup broad spectrum spf 25 creamy beige expert finish makeup broa... | OTC monograph final | 2021-05-20 |
Indication | Ontology | MeSH | ICD-10 |
|---|---|---|---|
| hepatitis c | — | D006526 | B19.2 |
| chronic hepatitis c | EFO_0004220 | D019698 | B18.2 |
Expiration | Code | ||
|---|---|---|---|
SOFOSBUVIR / VELPATASVIR, EPCLUSA, GILEAD SCIENCES INC | |||
| 2028-12-10 | PED | ||
| 2028-06-10 | ODE-376 | ||
| 2027-09-19 | PED | ||
| 2027-03-19 | ODE-293 | ||
| 2025-04-27 | M-277 | ||
| 2024-01-14 | PED | ||
| 2023-09-19 | PED | ||
| 2023-07-14 | M-264 | ||
| 2023-05-15 | PED | ||
| 2023-03-19 | NPP, NS | ||
LEDIPASVIR / SOFOSBUVIR, HARVONI, GILEAD SCIENCES INC | |||
| 2026-08-28 | ODE*, ODE-262, ODE-263, ODE-264 | ||
| 2024-10-07 | PED | ||
| 2024-04-07 | ODE*, ODE-136 | ||
SOFOSBUVIR, SOVALDI, GILEAD SCIENCES INC | |||
| 2026-08-28 | ODE*, ODE-258 | ||
| 2024-10-07 | PED | ||
| 2024-04-07 | ODE*, ODE-135 | ||
Patent | Expires | Flag | FDA Information |
|---|---|---|---|
| Sofosbuvir / Velpatasvir / Voxilaprevir, Vosevi, Gilead Sciences Inc | |||
| 10912814 | 2037-06-01 | DP | |
| 11338007 | 2037-06-01 | DP | U-2039, U-2040 |
| 9296782 | 2034-07-17 | DS, DP | |
| 9868745 | 2032-11-16 | DS, DP | |
| 8957046 | 2028-03-21 | U-2039, U-2040 | |
| Sofosbuvir / Velpatasvir, Epclusa, Gilead Sciences Inc | |||
| 9757406 | 2034-01-30 | DP | |
| 10086011 | 2034-01-30 | U-1470 | |
| 11116783 | 2034-01-30 | DP | U-1470, U-2039, U-2040 |
| 11707479 | 2034-01-30 | DP | U-1470 |
| 8575135 | 2032-11-16 | DS, DP | U-1470, U-2039, U-2040 |
| 8921341 | 2032-11-16 | DS, DP | U-1470, U-2039, U-2040 |
| 8940718 | 2032-11-16 | DS, DP | U-1470, U-2039, U-2040 |
| Ledipasvir / Sofosbuvir, Harvoni, Gilead Sciences Inc | |||
| 10039779 | 2034-01-30 | DS, DP | U-1470, U-2369, U-2370 |
| 9393256 | 2032-09-14 | U-1470 | |
| 10456414 | 2032-09-14 | DP | |
| 8618076 | 2030-12-11 | DS, DP | U-1470, U-2039, U-2040 |
| 9284342 | 2030-09-13 | DS, DP | U-1470, U-2039, U-2040 |
| 8088368 | 2030-05-12 | DS, DP | |
| 8273341 | 2030-05-12 | U-1470 | |
| 8822430 | 2030-05-12 | DS, DP | U-1470 |
| 8841278 | 2030-05-12 | DP | U-1470 |
| 9511056 | 2030-05-12 | DP | U-1470 |
| 7964580 | 2029-03-26 | DS, DP | U-1470, U-2039, U-2040 |
| 8633309 | 2029-03-26 | DS, DP | U-1470, U-2039, U-2040 |
| 8889159 | 2029-03-26 | DP | U-1470, U-2039, U-2040 |
| 8334270 | 2028-03-21 | DS, DP | U-1470, U-2039, U-2040 |
| 8580765 | 2028-03-21 | DS, DP | U-1470, U-2039, U-2040 |
| 8735372 | 2028-03-21 | U-1470, U-2039, U-2040 | |
| 9085573 | 2028-03-21 | DS, DP | U-1470, U-2039, U-2040 |
| Sofosbuvir, Sovaldi, Gilead Sciences Inc | |||
| 9549941 | 2029-03-26 | U-1958 | |

Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Hepatitis c | D006526 | — | B19.2 | 7 | 48 | 39 | 10 | 16 | 118 |
| Hepatitis | D006505 | — | K75.9 | 4 | 21 | 22 | 4 | 7 | 57 |
| Chronic hepatitis c | D019698 | EFO_0004220 | B18.2 | 3 | 14 | 18 | 9 | 6 | 50 |
| Hepatitis b | D006509 | — | — | 1 | 21 | 21 | 1 | 3 | 47 |
| Hepatitis a | D006506 | EFO_0007305 | B15 | 4 | 10 | 8 | 2 | 5 | 28 |
| Acquired immunodeficiency syndrome | D000163 | EFO_0000765 | B20 | — | 1 | 4 | 1 | 1 | 7 |
| Hiv infections | D015658 | EFO_0000764 | B20 | — | 1 | 2 | 1 | 1 | 5 |
| Coinfection | D060085 | — | — | — | 1 | 3 | 1 | — | 5 |
| Opioid-related disorders | D009293 | EFO_0005611 | F11 | — | — | — | 3 | — | 3 |
| Metabolic bone diseases | D001851 | — | — | — | — | — | 1 | — | 1 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Infections | D007239 | EFO_0000544 | — | 1 | 20 | 17 | — | 1 | 39 |
| Communicable diseases | D003141 | — | — | 1 | 18 | 13 | — | — | 32 |
| Virus diseases | D014777 | — | B34 | 1 | 5 | 5 | — | 1 | 11 |
| Hepacivirus | D016174 | — | — | — | 2 | 2 | — | 3 | 7 |
| Fibrosis | D005355 | — | — | — | 1 | 5 | — | 1 | 7 |
| Hiv | D006678 | — | O98.7 | 1 | 1 | 4 | — | 1 | 6 |
| Liver diseases | D008107 | EFO_0001421 | K70-K77 | — | 3 | 1 | — | 1 | 5 |
| Chronic hepatitis | D006521 | — | K73.9 | — | 2 | 1 | — | 1 | 4 |
| Rna virus infections | D012327 | — | — | — | 1 | 1 | — | 1 | 3 |
| Digestive system diseases | D004066 | EFO_0000405 | K92.9 | — | 1 | 1 | — | 1 | 3 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Chronic kidney failure | D007676 | EFO_0003884 | N18.6 | — | 3 | — | — | — | 3 |
| Hemophilia a | D006467 | EFO_0007267 | D66 | — | 1 | — | — | — | 1 |
| Chronic hepatitis b | D019694 | EFO_0004239 | B18.1 | — | 1 | — | — | — | 1 |
| Portal hypertension | D006975 | EFO_0000666 | K76.6 | — | 1 | — | — | — | 1 |
| Hepatocellular carcinoma | D006528 | — | C22.0 | — | 1 | — | — | — | 1 |
| Liver neoplasms | D008113 | EFO_1001513 | C22.0 | — | 1 | — | — | — | 1 |
| Hepatitis e | D016751 | EFO_0007303 | — | — | 1 | — | — | — | 1 |
| Porphyria cutanea tarda | D017119 | — | E80.1 | — | 1 | — | — | — | 1 |
| Sickle cell anemia | D000755 | EFO_0000697 | D57 | — | 1 | — | — | — | 1 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Lung transplantation | D016040 | — | — | 1 | — | — | — | — | 1 |
| Pregnancy | D011247 | EFO_0002950 | Z33.1 | 1 | — | — | — | — | 1 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Recreational drug use | D000084783 | — | — | — | — | — | — | 1 | 1 |
| Pregnancy complications | D011248 | — | — | — | — | — | — | 1 | 1 |
| Drug common name | Sofosbuvir |
| INN | sofosbuvir |
| Description | Sofosbuvir is a nucleotide conjugate that is used in combination with ledipasvir (under the trade name Harvoni) for the treatment of chronic hepatitis C genotype 1 infection. It has a role as a prodrug, an antiviral drug and a hepatitis C protease inhibitor. It is a L-alanyl ester, a phosphoramidate ester, a nucleotide conjugate, an organofluorine compound and an isopropyl ester. It is functionally related to a uridine 5'-monophosphate. |
| Classification | Small molecule |
| Drug class | phosphoro-derivatives; antivirals: RNA polymerase (NS5B) inhibitors |
| Image (chem structure or protein) | ![]() |
| Structure (InChI/SMILES or Protein Sequence) | CC(C)OC(=O)[C@H](C)N[P@](=O)(OC[C@H]1O[C@@H](n2ccc(=O)[nH]c2=O)[C@](C)(F)[C@@H]1O)Oc1ccccc1 |
| PDB | — |
| CAS-ID | 1190307-88-0 |
| RxCUI | — |
| ChEMBL ID | CHEMBL1259059 |
| ChEBI ID | 85083 |
| PubChem CID | 45375808 |
| DrugBank | DB08934 |
| UNII ID | WJ6CA3ZU8B (ChemIDplus, GSRS) |














